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ABSTRACT
Spinal Muscular Atrophy (SMA) is a neuromuscular
disorder caused by insufficient levels of the Survival
of Motor Neuron (SMN) protein. SMN is expressed
ubiquitously and functions in RNA processing path-
ways that include trafficking of mRNA and assem-
bly of snRNP complexes. Importantly, SMA severity
is correlated with decreased snRNP assembly ac-
tivity. In particular, the minor spliceosomal snRNPs
are affected, and some U12-dependent introns have
been reported to be aberrantly spliced in patient cells
and animal models. SMA is characterized by loss
of motor neurons, but the underlying mechanism
is largely unknown. It is likely that aberrant splic-
ing of genes expressed in motor neurons is involved
in SMA pathogenesis, but increasing evidence indi-
cates that pathologies also exist in other tissues. We
present here a comprehensive RNA-seq study that
covers multiple tissues in an SMA mouse model. We
show elevated U12-intron retention in all examined
tissues from SMA mice, and that U12-dependent in-
tron retention is induced upon siRNA knock-down of
SMN in HeLa cells. Furthermore, we show that reten-
tion of U12-dependent introns is mitigated by ASO
treatment of SMA mice and that many transcriptional
changes are reversed. Finally, we report on missplic-
ing of several Ca2+ channel genes that may explain
disrupted Ca2+ homeostasis in SMA and activation of
Cdk5.
INTRODUCTION
Spinal Muscular Atrophy (SMA) is a devastating neuro-
muscular disorder that often causes death during infancy
and invariably leads to progressive loss of muscle strength
due to loss of motor neurons (1,2). The disorder is caused
by deletions or mutations in the SMN1 gene (3,4), while
SMN2, a secondary gene capable of expressing an iden-
tical Survival of Motor Neuron (SMN) protein, expresses
only a low amount of SMN due to predominant skipping
of exon 7. A pointmutation at position 6 in exon 7 of SMN2
eliminates an exonic splicing enhancer (ESE) recognized by
serine/arginine-rich splicing factor 1 (SRSF1) (5,6) and cre-
ates an exonic splicing silencer (ESS) recognized by het-
erogeneous nuclear ribonucleoprotein A1 (hnRNP A1) (7).
This ESS acts synergistically with other ESS motifs that
bind to hnRNP A1 and Sam68, and repress exon 7 inclu-
sion (8–11). This leads to the production of a truncated and
unstable protein (12).
SMN itself is a ubiquitously expressed protein best char-
acterized as a protein involved in the assembly of small
nuclear ribonucleic protein (snRNP) complexes, both the
catalytically active components of the spliceosome (13–15),
and the U7 snRNP (16), which is involved in the processing
of histone pre-mRNA (17).
SMN has also been reported to be directly involved in
intra-cellular transport of mRNA (reviewed in (18)), to reg-
ulate actin (19) and to function as a general regulator of
translation (20). Thus, SMN functions in many different
contexts, and the SMA phenotype may be the outcome of
the disruption of SMN function in one or several of these.
The question of whether or not SMA is entirely or par-
tially caused by a perturbation in the generation of the
snRNP repertoire, or by the loss of axonal-specific activ-
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ity remains unresolved. Several studies support the involve-
ment of specific axonal activities of SMN in SMA pathol-
ogy andmotor neuron function, in particular mRNA pack-
aging and trafficking (19,21–24), but the best characterized
and most well-established function of SMN is in the bio-
genesis and maintenance of snRNPs (13,25). Additionally,
an SMNmissense mutant that retains snRNP-assembly ac-
tivity is able to rescue the SMA phenotype in a mouse
model expressing the human SMN2 transgene (26), while
co-injection of purified snRNP complexes from HeLa cells
into fish embryos rescues motor axon development defects
in a zebrafish SMA model (27).
Widespread defects in splicing have been reported from
studies employing exon arrays, where it was observed that
the level of aberrant splicing increases with disease progres-
sion (28,29). In particular, the minor spliceosomal snRNPs
are affected by low levels of SMN (27,30,31), and SMN-
dependent alternative splicing of a few U12-dependent in-
trons has been reported previously (31). Moreover, alter-
native splicing of a U12-dependent intron in the Stasimon
gene was recently reported to result in defects in the neu-
ronal circuitry of Drosophila, and expression of the human
orthologue in a zebrafish SMA model rescued motor axon
defects (32).
While motor neurons are the cells most severely affected
by low levels of SMN, there is also evidence indicating that
SMA pathology may affect other cell types in other tissues
as well. In both human patients with severe SMA (33) and
severe SMAmousemodels (34–36), non-motor neuron cen-
tral nervous system (CNS) pathologies and disrupted en-
teric nervous system (ENS) signaling that may be related to
gastrointestinal dysfunction (37) have been reported. Addi-
tionally, liver defects have been reported in several mouse
models (38,39), while cardiac defects have been reported in
both human patients (40,41) and mouse models (38,42,43).
Furthermore, systemic antisense oligonucleotide (ASO)
therapy with subcutaneous injection is necessary for long-
term rescue of type I SMAmice (44), while restricting ASO
therapy to peripheral tissue reduces tissue necrosis and im-
proves motor function and survival (45). Treatment with
a 2′-O-(2-methoxyethyl)-modified ASO targeting ISS-N1
(9) designated ASO10-27/SMNRx/Nusinersen represents
a promising treatment for SMA and has recently completed
its clinical trials and is now in the process of FDA and EMA
approval. Recently, a microarray study on an induced adult
SMAmouse model demonstrated that this ASO rescues the
gene expression changes observed in adult SMA mice (46),
but little is known about the global effects of SMN restora-
tion with an ASO on the splicing dysregulation, in particu-
lar intron retention, in severe SMAmice, although pharma-
cological restoration of SMN levels with a small-molecule
drug has been shown to restore snRNA levels and correct a
few known aberrant splicing events (47). Importantly, ASO
therapy also offers the possibility to study the effect of a
postnatal increase in SMNprotein levels to identify changes
specifically related to the postnatal state versus those that
may arise due to delayed maturation during embryogenesis.
In the present study, we have usedRNA-seq to investigate
global changes in gene expression and alternative splicing
in multiple tissues at an early pre-symptomatic stage and at
a later symptomatic stage in an SMA mouse model. Fur-
thermore, for the first time we use RNA-seq to examine the
transcriptomic changes following ASO treatment targeting
ISS-N1 and in particular how U12-dependent intron splic-
ing is corrected in treated severe SMA mice.
MATERIALS AND METHODS
Antisense oligonucleotide treatment
The synthesis and purification of ASO10–29 (5′-
ATTCACTTTCATAATGCTGG-3′) MOE-modified
oligonucleotide with phosphorothioate backbone and all
5-methylcytosines were performed as described (48). The
oligonucleotides were dissolved in 0.9% saline. Mice treated
with either saline or 100 g/g body-weight ASO10-29 were
injected twice, once on postnatal day 0 (PND0) and once
on postnatal day 1 (PND1). The oligonucleotide or empty
saline solutions were injected subcutaneously into the
upper back with a 5 l syringe and 33-gauge custom
removable needle (Hamilton) as previously described (48).
Mouse tissue preparation
Mice used in the study were ‘Taiwanese’ SMA model mice
generated from an SMA type III model (44,49,50) with
a mean lifespan of ∼10–11 days. Mouse tissues were col-
lected on postnatal day 1 (PND1) and postnatal day 5
(PND5). Mice were sacrificed with CO2 asphyxiation and
organs/tissues were rinsed in saline, snap-frozen in liquid
N2 and stored at −80◦C until processing. For extraction
of RNA samples, tissues were pulverized in liquid N2 with
a mortar and pestle, and total RNA was purified with an
RNeasy Mini Kit and treated with RNase-free DNase I.
When possible, samples were gender-matched to include
two males and two females in each group.
SMN1 knockdown in HeLa cells
HeLa cells were transfected three separate times with
SMN1 siRNA (L-011108-00-0005, Dharmacon) using
RNAiMAX (Thermo Fisher Scientific) according to man-
ufacturer’s instructions. Forty-eight hours post transfec-
tion RNA was extracted using Isol-RNA lysis reagent (5
PRIME). Two replicate knockdowns were used in RNA-
sequencing. Knockdown was confirmed by Western blot-
ting using anti-SMN (SC-32313, Santa Cruz Biotechnol-
ogy) and anti-SRSF3 (SC-13510, Santa Cruz Biotechnol-
ogy) as a loading control.
RNA-seq library preparation and sequencing
RNA purity, integrity and concentration were determined
using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Inc., USA). Only RNA with a RIN value of 8.0 or higher
and a 28s/18s ratio ∼1.8 was taken forward for sample
preparation. Mouse spinal cord RNA samples were pro-
cessed for library construction following the manufactory
instructions (Illumina TruSeq RNA sample preparation v2
Guide, Part #15026495Rev.BFebruary 2012 – ‘Low sample
protocol’). In brief, 1g of total RNA from eachmousewas
used for library preparation. mRNA was purified, chemi-
cally fragmented for 8 min at 94◦C, and processed for first
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strand cDNA synthesis and then second strand synthesis.
Following several purification steps, the cDNA was then
end-repaired, purified, adenylated at the 3′-ends, and puri-
fied before adding the indexed adaptor sequences. TruSeq
RNA sample prep kit v2, set A, cat-RS-122-2001 was used
for indexing. Each library preparation was then enriched by
10 cycles of PCR, purified and finally validated in regard
to size and concentration. For sizing, libraries were ana-
lyzed on the Agilent 2100 Bioanalyzer using a DNA 1000
kit from Agilent Technologies. The Libraries were quanti-
fied by qPCR using the KaPa Library quantification Kits
(KaPa Biosystems, Cat KK4824) and a final concentration
of 15 pM denatured libraries were used for paired-end 75
bp sequencing on an Illumina HiSeq1500.
Mouse brain, liver, muscle, ASO treated tissue sam-
ples, and HeLa RNA samples were prepped for library se-
quencing following Illumina TruSeq Stranded Total RNA
Samples Preparation Guide, Part#15031048 Rev.E Octo-
ber 2013––‘Low sample protocol’. 0.5 g of total RNA
from each sample was depleted for cytoplasmic rRNAusing
the Ribo-Zero ribosomal reduction chemistry and subse-
quently purified before fragmentation and processing sim-
ilar to the protocol above. However, during second strand
synthesis, the incorporation of dUTP instead of dTTP
quenches the second strand during amplification, because
the polymerase does not amplify past this nucleotide, and
thereby the library becomes strand specific. For indexing,
the TruSeq Stranded LT Kit Index set A was used. Samples
were pooled in sets of 12 libraries, and a final concentration
of 16 pM denatured libraries were used for paired-end 100
bp sequencing using an Illumina HiSeq1500.
Raw sequencing data have been deposited in the Array-
Express database under accession E-MTAB-3664.
cDNA synthesis
0.5 or 1.0 g of total RNA was treated with DNase I
(Invitrogen, cat. 18068-015), and then reverse transcribed
into cDNA using the Superscript VILO cDNA kit (Invit-
rogen, cat. 11754-050). A reaction volume of 10 l was
used. cDNA synthesis was performed according to man-
ufactory instruction, but with an extended synthesis at
42◦C for 120 min. Subsequently, the cDNA was added
50 l DEPC-water and cDNA concentration was mea-
sured by absorbance readings at 260, 280 and 230 nm
(NanoDropTM1000 Spectrophotometer; Thermo Scientific,
CA, USA).
qPCR
Each cDNA (50–100 ng) was used in triplicates as template
for in a reaction volume of 8 l containing 3.33 l Fast
Start Essential DNA Green Master (2×) (Roche Diagnos-
tics, Hvidovre, Denmark), 0.33 l primer premix (contain-
ing 10 pmol of each primer), and PCR grade water to a to-
tal volume of 8 l. The qPCR was performed in a Light
Cycler LC480 (Roche Diagnostics, Hvidovre, Denmark): 1
cycle at 95◦C/5 min followed by 45 cycles at 95◦C/10 s, 59–
64◦C (primer dependent)/10 s, 72◦C/10 s. Primers used for
qPCR are listed in Supplementary Table S9. Threshold val-
ues were determined by the Light Cycler software (LCS480
1.5.1.62 SP1) using Absolute Quantification Analysis/2nd
derivative maximum. Each qPCR assay included; a stan-
dard curve of nine serial dilution (2-fold) points of a cDNA
mix of all the samples (250 to 0.97 ng), and a no-template
control. PCR efficiency ( = 10(-1/slope) − 1) were ≥70% and
r2 = 0.96 or higher. The specificity of each amplification
was analyzed by melting curve analysis. Quantification cy-
cle (Cq) was determined for each sample and the compara-
tive method was used to detect relative gene expression ra-
tio (2−Cq) normalized to the reference gene Vps29 in spinal
cord, brain, and liver samples, and E430025E21Rik in the
muscle samples. In HeLA samples, TBP was used as refer-
ence. Reference genes were chosen based on their observed
stability across conditions. Significance was ascertained by
the two-tailed Student’s t-test.
Bioinformatics analysis
Each sample was aligned using STAR (51) with the follow-
ing additional parameters: ‘–outSAMstrandField intron-
Motif –outFilterType BySJout’. The gender of each sample
was confirmed through Y chromosome coverage and RT-
PCR of Y-chromosome-specific genes (data not shown).
Gene-expression analysis. HTSeq (52) was used to obtain
gene-counts using the Ensembl v.67 (53) annotation as ref-
erence. The Ensembl annotation had prior to this been re-
stricted to genes annotated as protein-coding. Gene counts
were subsequently used as input for analysis with DESeq2
(54,55) usingR (56). Prior to analysis, genes with fewer than
four samples containing at least one read were discarded.
Samples were additionally normalized in a gene-wise man-
ner using conditional quantile normalization (57) prior to
analysis with DESeq2. Gene expression was modeled with
a generalized linear model (GLM) (58) of the form: expres-
sion ∼ gender + condition. Genes with adjusted P-values
<0.1 were considered significant, equivalent to a false dis-
covery rate (FDR) of 10%.
Differential splicing analysis. Exon-centric differential
splicing analysis was performed using DEXSeq (59) with
RefSeq (60) annotations downloaded fromUCSC, Ensembl
v.67 (53) annotations downloaded from Ensembl, and de
novo transcript models produced by Cufflinks (61) using
the RABT approach (62) and the Ensembl v.67 annota-
tion. We excluded the results of the analysis of endoge-
nous Smn, as the SMAmice only express the human SMN2
transgene correctly, but not the murine Smn gene, which
has been disrupted. Ensembl annotations were restricted to
genes determined to be protein-coding. To focus the anal-
ysis on changes in splicing, we removed significant exonic
regions that represented start or end regions within the tran-
script models, and were therefore not likely to be caused by
changes in splicing, but rather by alternative transcriptional
initiation or 3′-end formation. We did this by removing the
regions that shared either their start position with a start
position of a reference transcript, or their end position with
an end position of one of the reference transcripts. We di-
vided exonic regions into classes by the following criteria, in
descending order: regions that fully matched known exons
were classified as cassette exons; regions that were spanned
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by an upstream exonic region and a downstream intronwere
classified as alternative 5′ss; regions that were spanned by
a downstream exonic region and an upstream intron were
classified as alternative 3′ss; regions that had a start posi-
tion matching a known 5′ss and an end position matching a
known 3′ss were classified as retained introns; and regions
that did notmatch any of these criteria were classified as un-
categorized. Exon expression was modeled with a general-
ized linear model of the form: expression∼ gender + condi-
tion. DEXSeq was run with independent filtering turned off
in the DESeq2 package, as we found that this filter resulted
in loss of detection of SMN2 skipping in some analyses,
despite clear skipping. Cufflinks v. 2.1.1 was run using the
following parameters: ‘–max-multiread-fraction 0.5 -j 0.1′.
Cuffcompare v. 2.1.1 was used to assemble transcripts from
all samples into a non-redundant set. A custom Perl script
was used to sanitize the resulting GTF file before use with
DEXSeq by removing duplicate gene annotations on differ-
ent chromosomes or strands. U12-intron retention analysis
was performed usingDEXSeq andRefSeq annotations sup-
plemented with a non-redundant list of 835 U12-dependent
introns generated by combiningU12DBv2 (63) annotations
with introns in the Ensembl v.67 annotation that matched
the 5′ss-3′ss consensus AT-AC or GTATCCT-AG. The set
of genes analyzed was restricted to only those genes with at
least one U12-intron. Similarly, for hg38 we generated a list
of 1057 introns in 764 genes using U12DBv2 and Ensembl
hg38 annotation version 79.
Pathway analysis. GO pathway analysis was performed
using GOseq (64) while significantly expressed KEGG
pathways were identified using Gage (65) and visualized us-
ing Pathview (66). Pathways with adjusted P-values below
0.1 were considered significant.
Coverage profiles. To compare coverage profiles between
groups, we used Gviz (67) to plot the average of the four
samples in each group. Prior to this, coverage of each sample
had been normalized using size factors calculated by cqn.
RESULTS
We first collected tissue samples from severe SMAmice (68)
sacrificed on postnatal day 1 (PND1) and postnatal day
5 (PND5). These time points were selected to allow us to
compare an early pre-symptomatic stage with a later symp-
tomatic stage. Additionally, at PND5, treatment with ASO
therapy can only weakly delay disease progression (44,48),
indicating that by this time point the disease has reached a
critical stage. We collected tissue samples from spinal cord,
brain, liver, and skeletal muscle, extracted total RNA and
performed RNA-seq on 4 SMA mice and 4 litter-matched
heterozygous control mice from each time point.
Few changes in gene expression at postnatal day 1
We first examined changes in gene expression between
SMAmice and heterozygous mice at PND1 and PND5. At
PND5, principal component analysis (PCA) indicated large
differences between the two groups, and also that male and
female SMA mice respond differently, as indicated by gen-
der grouping in the spinal cord and liver samples (Supple-
mentary Figures S1 and S2).We therefore accounted for the
effect of gender in subsequent analyses (see Materials and
Methods). At PND1, we identified only few differentially
expressed genes at false-discovery rate (FDR) less than 10%
or 0.1 (Figure 1A and Supplementary Figures S4 and S5,
Table S7 and S8). By contrast, we identified several thou-
sand genes up- or down-regulated at FDR< 0.1 in the SMA
mice at PND5 (Figure 1A, Supporting data S1). These num-
bers indicate that among the tissues examined, the spinal
cord and liver are affected more severely or that they are
responding more strongly to the decrease in levels of SMN.
We identified only few differences at PND1 in the spinal
cord, brain and liver samples (Figure 1A) and PCA also in-
dicated little overall difference between SMAmice and their
heterozygous littermates (Supplementary Figure S1A and
C, S2A and C).
Comparison of differentially expressed genes across tis-
sues showed considerable overlap at PND5, however, only
one gene at PND1 was differentially expressed in all tissues.
This could be in part because there were generally few dif-
ferentially expressed genes at PND1 (Figure 1B). The gene,
Snrpa1, was up-regulated in all tissues both at PND1 and
at PND5, and was also observed to be up-regulated at P7
in the 7 mouse model in an earlier microarray study (29).
It is especially interesting since it encodes the A’ polypep-
tide that is part of the mature U2 snRNP (69), indicating a
possible effect on splicing.
When we compared the log2 fold-changes at PND5 in
spinal cord versus the log2 fold-changes in other tissues, it
was clear that the direction of change was generally main-
tained, pointing to activation and deactivation of similar
pathways in the different tissues (Figure 1C). There was a
common overlap of 124 genes between all tissues, and 110
of these were either up-regulated in all tissues, or down-
regulated in all tissues. Gene ontology (GO) analysis identi-
fied several down-regulated GO terms, in particular angio-
genesis (Supporting data S3), indicating that limited supply
of growth factors and nutrients may be a contributing fac-
tor to SMA pathogenesis in several tissues.
We further examined the degree of agreement between
PND1 and PND5 by comparing the log2 fold-change es-
timates of the differentially expressed genes at PND1 with
their log2 fold-changes at PND5 (Figure 1D, Supporting
data S2). In the spinal cord, there were 33 significantly
altered genes at PND1, and linear regression analysis on
these genes showed overall agreement between the two time
points. Similarly, in the brain there was a high correlation
between the two time points particularly for those genes
that were significantly changed at both time-points. Corre-
lation was also observed between the overlap of genes in
muscle and liver. Taken together, these data indicate that
the changes of gene expression levels represent a consistent
response to decreasing levels of SMN protein.
Cell division is down-regulated in SMA mice at PND5 while
stress-genes are up-regulated
To identify the overall cellular pathways that are signifi-
cantly altered in the tissues of SMAmice, we performedGO
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Figure 1. Gene expression analysis. (A) Barplot showing the number of differentially expressed genes in SMA-like mice at PND1 and PND5 in spinal cord,
brain, liver and muscle. The number of down- and up-regulated genes is indicated below the barplot. (B) Venn diagrams of the overlap of significant genes
in different tissues at PND1 and PND5. (C) Scatterplots of log2 fold-change estimates in spinal cord, brain, liver and muscle. Genes that were significant
in both conditions are indicated in purple, genes that were significant only in the condition on the x axis are indicated in red, genes significant only in
the condition on the y axis are indicated in blue. (D) Scatterplots of log2 fold-changes of genes in the indicated tissues that were statistically significantly
different at PND1 versus the log2 fold-changes at PND5. Genes that were also statistically significantly different at PND5 are indicated in red. The dashed
grey line indicates a completely linear relationship, the blue line indicates the linear regression model based on the genes significant at PND1, and the red
line indicates the linear regression model based on genes that were significant at both PND1 and PND5. Pearsons rho is indicated in black for all genes
significant at PND1, and in red for genes significant at both time points.
enrichment analysis on the significant genes (Supporting
data S4–7). This analysis indicated that pathways and pro-
cesses associated with cell-division were significantly down-
regulated in the spinal cord at PND5, in particular mitotic-
phase genes (Supporting data S4). In a recent study using
an inducible adult SMAmouse model, reduced cell division
was reported as one of the primary affected pathways that
could be reversed with ASO treatment (46). In particular,
up-regulation of Cdkn1a and Hist1H1C were reported as
the most significant genotype-driven changes and similarly
we observe the same up-regulation in spinal cord at PND5.
There were no significantly enriched GO terms when we an-
alyzed the up-regulated genes, but we did observe an up-
regulation of Mt1 and Mt2 (Figure 2B), which are metal-
binding proteins up-regulated in cells under stress (70,71).
These two genes are also among the genes that were up-
regulated in all tissues at PND5 and, notably, they were
also up-regulated at PND1 in several tissues (Figure 2C).
This indicates that while there were few overall differences
at PND1 between SMA and heterozygous mice, increased
cellular stress was apparent at the pre-symptomatic stage.
Furthermore, GO terms associated with angiogenesis were
down-regulated, and we observed the same at PND5 in the
brain, where these were among the most significantly down-
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Figure 2. Expression of axon guidance genes is down-regulated in SMA-like mice at PND5 while stress genes are up-regulated. (A) Schematic depiction
of the axon guidance pathway in mice from the KEGG database. Gene regulation is indicated by a color gradient going from down-regulated (blue) to
up-regulated (red) with the extremity thresholds of log2 fold-changes set to−1.5 and 1.5, respectively. (B) qPCR validation of differentially expressed genes
in SMA-like mice at PND5. (C) qPCR validation of differentially expressed genes in SMA-like mice at PND1. Error bars indicate SEM, n ≥ 3, **P-value
< 0.01, *P-value < 0.05. White bars indicate heterozygous control mice, grey bars indicate SMA-like mice.
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regulated GO terms (Supporting data S5). Likewise, angio-
genesis seemed to be affected in the liver and the muscles
(Supporting data S6 and S7), and in the muscles the cell cy-
cle seemed to be down-regulated. The PI3K–Akt signaling
pathway was down-regulated in the liver at PND5, also in-
dicating impaired cellular growth (Supporting data S6) and
in line with the adult induced SMA mouse model (46).
Axon guidance genes Cxcl12 and Cxcr4 are down-regulated
at PND5
We observed significantly altered KEGG pathways (Kyoto
Encyclopedia of Genes and Genomes; Supporting data S4–
7) and significant down-regulation of the axon-guidance
pathway in spinal cord at PND5 (Tables 1 and 2). Some of
the most strongly down-regulated genes were Cxcl12 and
its receptor, Cxcr4 (Figure 2A, Table 2). When we exam-
ined expression of these genes across all samples by qPCR,
we found Cxcl12 to be down-regulated in brain and liver
as well, but not at PND1 (Figure 2B), while Cxcr4 also ap-
peared to be down-regulated in several tissues.
Expression of spurious transcripts via novel splice sites in
SMA mice
The hypothesis that SMA pathogenesis is linked to aber-
rant splicing has been proposed in the past (15,27) and by
this reasoning, it is likely that SMA cells produce aberrant
transcripts that are not observable in normal cells. To inves-
tigate this scenario, we examined alternative splicing using
increasingly comprehensive and diverse transcript annota-
tions to distinguish aberrant splicing from regulated alter-
native splicing. RNA-seq is particularly well suited for the
analysis of aberrant splicing, such as intron retention, rela-
tive to exon-arrays, which generally fail to detect any signal
from expressed intronic sequences.
When we analyzed alternative splicing in the spinal cord
with the RefSeq annotation (60) and compared it with the
Ensembl annotation (53), we found an increase in the num-
ber of detected alternative splicing events that was approx-
imately 4–6 times higher than expected from the increase
in annotation size alone (Figure 3A, Supporting data S8
and S9). The increase in the number of differentially ex-
pressed regions was higher at PND5, indicating that the in-
crease was not only due to the increased number of regions.
Similarly, in brain, liver, and muscle, there was an increased
number of differentially regulated exonic regions when us-
ing the Ensembl reference (Table 3). In muscle, the increase
was not as pronounced as in the other tissues and was in
fact in line with the increase in annotation complexity (Fig-
ure 3A, Table 3), but we identified fewer down-regulated
exonic regions with the Ensembl annotation. We also ob-
served the largest number of alternatively regulated exonic
regions with the RefSeq annotation in the muscle, which ex-
plains why the relative increase is lower.
While the Ensembl annotation likely contains many tran-
scripts that are non-functional and therefore can be de-
scribed as aberrant, it does not contain all possible tran-
scripts that can be expressed from all genes, and in partic-
ular it lacks transcripts that are expressed in cells with dys-
functional splicing due to a pathological condition. In or-
der to detect these spurious transcripts, we used Cufflinks
(61,62), to assemble the RNA-seq reads into novel tran-
scripts using the reference-guided algorithm with the En-
sembl annotation as reference. By this approach, we identi-
fied 9 differentially expressed exonic regions in seven genes
in the spinal cord at PND1, and 668 exonic regions in 517
genes at PND5, at 10% FDR (Table 3, Supporting data
S10). Again, the relative increase in the number of differen-
tially expressed regions at PND5 between the Ensembl and
Cufflinks derived annotations (72.6%) surpasses the relative
increase in total exonic regions (21.1%) and becausemost of
the differentially expressed regions were up-regulated (533),
we conclude that spurious and likely aberrant transcripts
are preferentially up-regulated in the spinal cord of SMA
mice at PND5. Further corroborating this hypothesis, we
observed that of the 668 differentially expressed regions, 243
(36.5%) did not overlap any of the known exonic regions
in the RefSeq and Ensembl annotations, and of these, 220
(90.2%) were up-regulated in SMA mice, whereas only 23
(9.8%) were down-regulated. In the brain, liver and muscle,
the results were similar with large increases at both PND1
and PND5 in the number of detected alternative splicing,
and most of the de-novo exonic regions were up-regulated in
the SMA mice (Figure 3A, Table 3, Supporting data S10).
A comparison of the genes with alternative splicing us-
ing the Cufflinks annotation between tissues (Figure 3B,
Supplementary Figure S8) shows that most of the aberrant
splicing was tissue-specific, as there was a relatively small
overlap in the number of genes alternatively spliced in mul-
tiple tissues. Only two genes were alternatively spliced in all
tissues at significant levels, albeit in differentways:Srsf5 and
Srsf10, both of which are SR proteins that regulate splicing.
We speculate that expression of SR proteins may be partic-
ularly sensitive to altered splicing fidelity, as they are known
to regulate themselves and other SR proteins through alter-
native splicing (72–75). Changes in the splicing of splicing
regulatory genes was also observed in another recent mi-
croarray study of SMA mice (76).
U2-dependent introns are retained in SMA mice
We then examined the patterns of alternative splicing by
categorizing the exonic regions based on their overlap with
the overall transcript structure (see Materials and Meth-
ods). The most prevalent type of missplicing detected with
the RefSeq annotation was alternative cassette exon splic-
ing (Table 4, Supplementary Figure S9), whereas analysis
with the Ensembl annotation indicated that not only alter-
native 3′ and 5′ splice sites were being activated, but also
that increased intron retention was prevalent in SMAmice.
When we analyzed alternative splicing using the Cufflinks-
derived annotation, pronounced intron retention became
more evident, particularly in the spinal cord tissue, where
the number of alternative splicing events increased consid-
erably. More specifically, the aberrantly spliced transcripts
were generally up-regulated in SMA mice (Figure 3C) and
the majority was of the intron-retention type (Figure 3D).
This pattern was even more pronounced when we examined
only the novel regions, where more than three out of four
novel splicing events were intron-retention. The same was
true for the other tissues, indicating that increased intron
retention is a tissue-wide phenomenon in SMA mice.
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Table 1. The significantly down-regulated KEGG pathways in spinal cord at PND5
Pathway P-value q-value No. of genes in pathway
mmu04110 Cell cycle 1.31E−07 3.60E−05 122
mmu04360 Axon guidance 6.90E−06 0.000953 128
mmu04114 Oocyte meiosis 0.000354 0.032538 106
mmu04914 Progesterone-mediated oocyte maturation 0.001139 0.078583 86
mmu05206 MicroRNAs in cancer 0.001614 0.089089 140
Table 2. Significantly differentially expressed genes in the axon guidance pathway at PND5 in the spinal cord
Ensembl ID Symbol Description log2FoldChange P-value padj
ENSMUSG00000029710 Ephb4 Eph receptor B4 [Source:MGI Symbol;Acc:MGI:104757] −0.61541736 3.59E−10 2.33E−08
ENSMUSG00000045382 Cxcr4 chemokine (C-X-C motif) receptor 4 [Source:MGI
Symbol;Acc:MGI:109563]
−0.982131677 1.16E−09 6.75E−08
ENSMUSG00000020099 Unc5b unc-5 homolog B (C. elegans) [Source:MGI Symbol;Acc:MGI:894703] −0.498514056 6.92E−08 2.86E−06
ENSMUSG00000061353 Cxcl12 chemokine (C-X-C motif) ligand 12 [Source:MGI
Symbol;Acc:MGI:103556]
−1.129675774 9.65E−08 3.84E−06
ENSMUSG00000026259 Ngef neuronal guanine nucleotide exchange factor [Source:MGI
Symbol;Acc:MGI:1858414]
−0.370710424 4.43E−07 1.57E−05
ENSMUSG00000027852 Nras neuroblastoma ras oncogene [Source:MGI Symbol;Acc:MGI:97376] −0.277599616 2.52E−06 7.19E−05
ENSMUSG00000032562 Gnai2 guanine nucleotide binding protein (G protein), alpha inhibiting 2
[Source:MGI Symbol;Acc:MGI:95772]
−0.325593742 7.26E−06 0.000180106
ENSMUSG00000030539 Sema4b sema domain, immunoglobulin domain (Ig), transmembrane domain (TM)
and short cytoplasmic domain, (semaphorin) 4B [Source:MGI
Symbol;Acc:MGI:107559]
0.375467998 3.07E−05 0.000614462
ENSMUSG00000027954 Efna1 ephrin A1 [Source:MGI Symbol;Acc:MGI:103236] −0.624353799 3.38E−05 0.000662811
ENSMUSG00000029095 Ablim2 actin-binding LIM protein 2 [Source:MGI Symbol;Acc:MGI:2385758] 0.237941574 0.000103113 0.001693553
ENSMUSG00000056427 Slit3 slit homolog 3 (Drosophila) [Source:MGI Symbol;Acc:MGI:1315202] 0.507131782 0.000143304 0.002233933
ENSMUSG00000031217 Efnb1 ephrin B1 [Source:MGI Symbol;Acc:MGI:102708] −0.503547146 0.000180732 0.002694972
ENSMUSG00000031391 L1cam L1 cell adhesion molecule [Source:MGI Symbol;Acc:MGI:96721] −0.300231258 0.000318591 0.004288775
ENSMUSG00000029168 Dpysl5 dihydropyrimidinase-like 5 [Source:MGI Symbol;Acc:MGI:1929772] −0.399882167 0.00033427 0.004474746
ENSMUSG00000028664 Ephb2 Eph receptor B2 [Source:MGI Symbol;Acc:MGI:99611] −0.320932658 0.000447098 0.005638681
ENSMUSG00000026640 Plxna2 plexin A2 [Source:MGI Symbol;Acc:MGI:107684] −0.292021681 0.000631786 0.007465337
ENSMUSG00000022048 Dpysl2 dihydropyrimidinase-like 2 [Source:MGI Symbol;Acc:MGI:1349763] −0.196633206 0.000719297 0.008222821
ENSMUSG00000025810 Nrp1 neuropilin 1 [Source:MGI Symbol;Acc:MGI:106206] −0.304492143 0.001188028 0.012042472
ENSMUSG00000059921 Unc5c unc-5 homolog C (C. elegans) [Source:MGI Symbol;Acc:MGI:1095412] −0.305730412 0.002565788 0.022064245
ENSMUSG00000031398 Plxna3 plexin A3 [Source:MGI Symbol;Acc:MGI:107683] −0.265106665 0.002827641 0.023693623
ENSMUSG00000003070 Efna2 ephrin A2 [Source:MGI Symbol;Acc:MGI:102707] −0.222009429 0.003008549 0.024887771
ENSMUSG00000021904 Sema3g sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3G [Source:MGI Symbol;Acc:MGI:3041242]
−0.396876592 0.004839997 0.035346239
ENSMUSG00000005958 Ephb3 Eph receptor B3 [Source:MGI Symbol;Acc:MGI:104770] −0.239324667 0.005089011 0.036761342
ENSMUSG00000033220 Rac2 RAS-related C3 botulinum substrate 2 [Source:MGI
Symbol;Acc:MGI:97846]
0.422992771 0.005092864 0.036770732
ENSMUSG00000052133 Sema5b sema domain, seven thrombospondin repeats (type 1 and type 1-like),
transmembrane domain (TM) and short cytoplasmic domain,
(semaphorin) 5B [Source:MGI Symbol;Acc:MGI:107555]
0.194938034 0.005121675 0.036904754
ENSMUSG00000059810 Rgs3 regulator of G-protein signaling 3 [Source:MGI
Symbol;Acc:MGI:1354734]
−0.276075209 0.006178853 0.042220205
ENSMUSG00000030084 Plxna1 plexin A1 [Source:MGI Symbol;Acc:MGI:107685] −0.187031083 0.006338726 0.042964265
ENSMUSG00000019647 Sema6a sema domain, transmembrane domain (TM), and cytoplasmic domain,
(semaphorin) 6A [Source:MGI Symbol;Acc:MGI:1203727]
−0.179636461 0.010602229 0.062109349
ENSMUSG00000052504 Epha3 Eph receptor A3 [Source:MGI Symbol;Acc:MGI:99612] −0.418474638 0.012227601 0.068266031
ENSMUSG00000074785 Plxnc1 plexin C1 [Source:MGI Symbol;Acc:MGI:1890127] −0.29161526 0.012574303 0.069634854
ENSMUSG00000028289 Epha7 Eph receptor A7 [Source:MGI Symbol;Acc:MGI:95276] −0.25772596 0.012614666 0.069702846
ENSMUSG00000020121 Srgap1 SLIT-ROBO Rho GTPase activating protein 1 [Source:MGI
Symbol;Acc:MGI:2152936]
−0.146573343 0.013646582 0.073758114
ENSMUSG00000029674 Limk1 LIM-domain containing, protein kinase [Source:MGI
Symbol;Acc:MGI:104572]
0.149975362 0.015313998 0.079827523
ENSMUSG00000029765 Plxna4 plexin A4 [Source:MGI Symbol;Acc:MGI:2179061] −0.206671388 0.017069775 0.086229278
ENSMUSG00000053646 Plxnb1 plexin B1 [Source:MGI Symbol;Acc:MGI:2154238] 0.180639586 0.019246017 0.094148523
ENSMUSG00000022781 Pak2 p21 protein (Cdc42/Rac)-activated kinase 2 [Source:MGI
Symbol;Acc:MGI:1339984]
−0.192645617 0.020665462 0.098401758
The genes are sorted by their P-value.
Table 3. Number of differentially expressed exonic regions at PND1 and PND5
Spinal cord Brain Liver Muscle
Reference Regulation PND1 PND5 PND1 PND5 PND1 PND5 PND1 PND5
Refseq Up 0 30 1 17 4 124 13 387
Down 3 50 1 14 4 124 1 285
Ensembl Up 1 296 2 43 8 331 19 477
Down 6 92 3 31 7 175 4 279
Cufflinks Up 1 533 8 73 11 585 30 582
Down 8 135 2 41 10 283 10 290
Novel (Cufflinks) Up 1 220 4 20 2 188 8 69
Down 2 23 0 7 5 19 0 15
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Figure 3. Aberrant splicing with increased U2-intron retention in SMA-like mice. (A) Barplots showing the number of regions relative to the RefSeq
annotation, either the total set of annotated regions, or those significantly alternatively spliced at PND1 or PND5 in the indicated tissues. (B) Venn
diagram showing the overlap of genes with alternative splicing between tissues at PND5. (C) Volcano plots of exonic regions in spinal cord, brain, liver and
muscle at PND5. Significantly differentially expressed regions overlapping known transcripts are indicated in red, novel significant regions are indicated in
blue. Values exceeding chart limits are plotted at the corresponding edge and indicated by either up or downward facing triangle, or left/right facing arrow
heads. Number of known and novel regions that are up or down-regulated are indicated in red (known) and blue (novel) in either the upper-left (down)
or upper-right (up). (D) Piecharts of observed alternative splicing patterns in spinal cord, brain, liver and muscle at PND5 in either the full Cufflinks
annotation or only the novel regions not overlapping previously annotated transcripts.
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Table 4. Categorization of differentially expressed exonic regions using different annotations
Spinal cord Brain Liver Muscle
RefSeq RefSeq RefSeq RefSeq
Region PND1 PND5 PND1 PND5 PND1 PND5 PND1 PND5
Cassette exon 2 69 2 28 8 225 12 642
Alt 3′ss 0 2 0 0 0 7 1 7
Alt 5′ss 1 3 0 3 0 5 1 10
Intron retention 0 6 0 0 0 11 0 13
Uncategorized 0 0 0 0 0 0 0 0
Ensembl Ensembl Ensembl Ensembl
PND1 PND5 PND1 PND5 PND1 PND5 PND1 PND5
Cassette exon 3 134 2 41 9 255 15 507
Alt 3′ss 0 11 1 5 1 34 0 36
Alt 5′ss 1 12 1 3 1 37 1 62
Intron retention 3 230 1 25 4 180 7 147
Uncategorized 0 0 0 0 0 0 0 3
Cufflinks Cufflinks Cufflinks Cufflinks
PND1 PND5 PND1 PND5 PND1 PND5 PND1 PND5
Cassette exon 4 154 3 52 10 372 23 499
Alt 3′ss 0 26 1 9 1 52 1 48
Alt 5′ss 1 26 1 4 1 57 3 82
Intron retention 4 460 5 49 9 381 13 235
Uncategorized 0 2 0 0 0 6 0 8
Novel (Cufflinks) Novel (Cufflinks) Novel (Cufflinks) Novel (Cufflinks)
PND1 PND5 PND1 PND5 PND1 PND5 PND1 PND5
Cassette exon 1 17 0 10 2 20 3 10
Alt 3′ss 0 10 0 3 0 15 0 8
Alt 5′ss 0 8 1 0 0 9 0 10
Intron retention 1 208 3 14 4 161 5 53
Uncategorized 0 0 0 0 0 2 0 3
U12-dependent intron retention occurs in all examined tissues
at PND5
Defective splicing of U12-dependent introns has previously
been hypothesized to be a disease mechanism in SMA
and has also been reported several times in SMA cells
(31,32), and we therefore focused our splicing analysis on
this class of introns. We noticed that some of the intron-
retention events identified with the Cufflinks annotation
were in fact U12-dependent introns (Supplementary Fig-
ure S9). This analysis only included U12-dependent introns
that were identified by Cufflinks. Therefore, to analyzeU12-
dependent introns more generally we generated a set of
U12-dependent introns by extracting 546 U12-dependent
introns contained in the U12DBv2 database (63) and by
extracting all introns in the Ensembl annotation that con-
tained either an AT at the donor and an AC at the acceptor,
or a GTATCCT sequence at the donor and an AG at the
acceptor, both of which are splice-site combinations specific
toU12-dependent introns (63).We then combined these an-
notations into a non-redundant set of 835 U12-dependent
introns in the mm9 genome.
We realize that this approach most likely does not iden-
tify all U12-dependent introns in the mouse genome. No-
tably those that are not in the U12DBv2 database or have a
different donor site than the AT or GTATCCT consensus
that we selected, in addition to those that are not annotated
as introns in the Ensembl annotation will be missed. How-
ever, we chose to be restrictive in order to avoid including
by mistake any non-U12 introns in the analysis.
Next, we constructed reference gene annotations with
transcripts containing these introns, as well as their nor-
mal transcripts from the RefSeq annotation. We further re-
stricted our analysis to genes with U12-dependent introns,
leaving us with 701 genes with one or more U12-dependent
introns. We then analyzed both PND1 and PND5 samples,
and using an FDR cut-off value of 0.1, we identified very
few significant changes at PND1, but observed marked in-
creases in the degree of retention of U12-dependent introns
at PND5 in the SMA samples (Figure 4A and B, Support-
ing data S11). Notably, these events were almost exclusively
up-regulated in the SMA samples, indicating increased re-
tention of these U12-dependent introns.
The cell cycle regulator Rasgrp3 is down-regulated in all tis-
sues and its U12-dependent intron 4 is retained in SMA mice
The overlap of genes with significant U12-dependent in-
tron retention at PND5 included a set of three genes, and
of these, the U12-dependent intron in Rasgrp3 was among
the most highly up-regulated in all tissues (Figure 4D, Sup-
porting data S11). Rasgrp3 is a regulator of the cell cycle
through activation of Ras proteins (77), and since down-
regulation of the cell cycle was a general feature of the SMA
tissues, aberrant intron 4 retention in Rasgrp3 may be one
of the events underlying this change. We validated the in-
crease in retention of the U12-dependent intron and the de-
crease of the levels of spliced Rasgrp3 by specific qPCR as-
says in all tissues, at both PND1 and PND5 (Figure 5 and
6).Since retention of the intron could lead to degradation of
the transcript via theNMDpathway due to a premature ter-
mination codon (PTC) in the U12-dependent intron (Sup-
plementary Figure S10), our observations point out that
aberrant retention of the U12-dependent intron in the Ras-
grp3 gene might be an underlying mechanism contributing
to deregulation of the cell cycle in SMA mice.
U12-dependent intron retention in genes important for neu-
ronal function
Loss ofMyo10 has recently been shown to inhibit axon out-
growth (78,79), and our RNA-seq data indicated that the
U12-dependent intron 6 inMyo10 is retained, although not
to a statistically significant degree. However, qPCR analy-
sis showed that the U12-dependent intron 6 in Myo10 was
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Figure 4. U12-intron retention increases with disease progression. (A) Volcano plots of U12-intron retention SMA-like mice at PND1 in spinal cord, brain,
liver andmuscle. Significantly differentially expressed introns are indicated in red. Non-significant introns with foldchanges> 2 are indicated in blue. Values
exceeding chart limits are plotted at the corresponding edge and indicated by either up or downward facing triangle, or left/right facing arrow heads. (B)
Volcano plots of U12-intron retention in SMA-like mice at PND5 in spinal cord, brain, liver and muscle. Significantly differentially expressed introns
are indicated in red. Non-significant introns with fold-changes >2 are indicated in blue. Values exceeding chart limits are plotted at the corresponding
edge and indicated by either up or downward facing triangle, or left/right facing arrow heads. (C) Venn diagram of the overlap of common significant
alternative U12-intron retention across tissue at PND1. (D) Venn diagram of the overlap of common significant alternative U12-intron retention across
tissue at PND1.
in fact retained more in SMA mice than in their control
littermates, and we observed significant intron retention at
PND5 in spinal cord, liver, and muscle (Figure 6) and a sig-
nificant decrease of splicedMyo10 in spinal cord at PND5
and in brain at both PND1 and PND5. These data suggest
thatMyo10missplicing could play a role in SMApathology.
Similarly, with qPCR we validated the up-regulation of
U12-dependent intron retention in the Cdk5, Srsf10, and
Zdhhc13 genes, which have all been linked to neuronal de-
velopment and function (80–83). Curiously, hyperactivity
of Cdk5 was recently reported to increase phosphorylation
of tau in SMA neurons (84). We observed increased reten-
tion of a U12-dependent intron in Cdk5 in both muscle
and liver at PND5, while it was slightly more retained in
the spinal cord, but at a very low level (Supporting data
S11, Supplementary Figure S11). Analysis using specific
qPCR assays confirmed up-regulation of the intron in liver
and muscle (Figure 6A and B) and also indicated down-
regulation of the spliced transcript in liver at PND1 (Figure
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Figure 5. Increased U12-dependent intron retention in SMAmice. (A) qPCR validation of U12-dependent intron retention at PND1 and PND5 in spinal
cord. (B) qPCR validation of U12-dependent intron retention at PND1 and PND5 in brain. (C) qPCR validation of U12-dependent intron retention
at PND1 and PND5 in liver. (D) qPCR validation of U12-dependent intron retention at PND1 and PND5 in muscle. Error bars indicate SEM, n ≥ 3,
***P-value < 0.001, **P-value < 0.01, *P-value < 0.05. White bars indicate heterozygous control mice, gray bars indicate SMA-like mice. Spl = spliced,
Unspl = unspliced/retained intron.
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Figure 6. Knockdown of SMN in HeLa cells recapitulate the findings in SMA mice. (A) Western blot of SMN-targeting siRNA (SMN) versus non-
targeting siRNA (NT) samples showing reduced expression of SMN protein. (B) Volcano-plot of U12-dependent intron retention in SMN-deficient HeLa
cells. Significantly differentially retained introns are indicated in red. Non-significant introns with fold-changes >2 are indicated in blue. Values exceeding
chart limits are plotted at the corresponding edge and indicated by upward facing triangle. (C) Venn diagram showing overlap of genes with U12-dependent
intron retention in SMA mice at PND5 and SMN depleted HeLa cells.
6A), while there was only minor intron retention in muscle
at PND1 (Figure 6B).
We also observed retention of the U12-dependent in-
tron in the Stasimon/Tmem41b gene that was previously re-
ported as misspliced (32), although at very low expression
levels. Since these earlier results indicated that Tmem41b is
spliced more aberrantly in some neurons than others, this
may result in overall small changes when examining total
spinal cord and also indicates that small changes may re-
flect highly biologically relevant changes in some cell popu-
lations.
In the spinal cord, a U12-dependent intron in Myh9
was retained, together with down-regulation ofMyh9 tran-
scripts in general. As in the case of Rasgrp3, this may be
due to a PTC being present within the U12-dependent in-
tron (Supplementary Figure S13). Validation with qPCR
confirmed the down-regulation of spliced Myh9 and up-
regulation of unsplicedMyh9 in both spinal cord and brain
(Figure 5A and B), whereas there was increased retention
of the U12-dependent intron in liver and muscle (Figure 5C
and D). This could indicate that the NMD pathway is more
effective in the CNS, and perhaps explain why we detected
more U12-dependent intron retention events in peripheral
tissue than in the CNS.
We therefore examined the relationship between U12-
dependent intron retention and gene expression (Supple-
mentary Figure S14). There was very little correlation in
the liver, followed by moderate correlation in spinal cord
and muscle. However, in the brain there was a clear inverse
linear relationship, indicating that NMD is an important
pathway in the brain. This may explain why we observed
fewer aberrant splicing events in this tissue compared the
other tissues. These results also corroborate the hypothesis
that increased retention of U12-dependent introns leads to
degradation of the transcripts.
Knock-down of SMN in HeLa cells recapitulates the U12-
dependent intron retention of the SMA mouse model
If SMA pathology is indeed related to a generalized defec-
tive splicing of U12-dependent introns, this defect should
be present in human cells as well. To examine this, we per-
formed siRNA mediated knock-down of SMN protein in
HeLa cells. After 48 hours we harvested the cells and con-
ducted RNA-seq on knock-down samples and controls pre-
pared with a non-targeting siRNA (Figure 6A).
As in the mice, there was a similar striking increase in
U12-dependent intron retention in the knock-down sam-
ples (Figure 6B), and many of the genes with affected U12-
dependent introns in the mice were also affected in HeLa
cells (Figure 6C, Supplementary Figure S15B). In total, 103
genes had U12-dependent intron retention in one or more
introns. There are likely several more introns in other genes
affected by the decrease in SMN levels. These early changes
in U12-dependent intron retention following reduced SMN
levels indicate that the effect on splicing is an early effect of
SMN decrease.
Overall, we observed relatively few significant changes
in gene expression compared to what we observed in mice,
only 110 genes had significantly altered expression (Supple-
mentary Figure S15A, Supporting data S1). Of note, how-
ever, there was an increase in the expression of several mi-
tochondrial genes, indicating an increased number of mito-
chondria in the cells. We did not detect changes in theMt1
and Mt2 homologues nor in CXCL12 or CXCR4, indicat-
ing that the same stress mechanisms observed in the mouse
tissues are not activated in the HeLa cell culture. Therefore,
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the U12-dependent intron retention is independent of the
stress response otherwise activated in SMA mice.
Supporting that splicing differences are more pro-
nounced than gene expression changes, we found splicing
changes in 778 genes when we used the same methodol-
ogy as previously described to examine splicing of known
and novel transcripts by Cufflinks and DEXSeq (Support-
ing data S10). Of these, 152 were intron retention events
even though this method does not specifically test for in-
tron retention, either U2 or U12-dependent, but relies on
Cufflinks including them in the set of transcripts. The over-
lap of genes alternatively spliced in the SMAmice andHeLa
SMN knockdown was generally small, only two genes were
consistently alternatively spliced in all tissues and in HeLa,
Srsf5 and Srsf10 (Supplementary Figure S15D). In the case
of Srsf5, the splicing events were different from what we ob-
served in the SMA mice; where we observed up-regulation
of a distal 5′ss and alternative splicing of an intron and
a cassette exon, we observed down-regulation of a distal
3′ss in the HeLa SMN knockdown. However, in the case
of Srsf10 the region alternatively spliced in the HeLa SMN
knockdown overlaps the dual U12-dependent introns that
were detected as retained by the Cufflinks/DEXSeq ap-
proach in the SMA mice.
Another gene with an intron consistently affected by
decreased SMN levels both in SMA mice and the HeLa
knock-down experiment was Baz1b, a transcription factor
and regulator of chromatin structure recently shown to reg-
ulate the transcription of neurodevelopmental genes (85).
Furthermore, Baz1b is involved in DNA damage response
(86), and DNA damage is increased in SMA mouse mod-
els, including the ‘Taiwanese’ model used in this study (87).
This suggests that Baz1b missplicing could lead to a reduc-
tion in DNA damage response. Furthermore, Baz1b also
regulates the maintenance of correct chromatin structure
during DNA replication (88), suggesting that Baz1b miss-
plicing might also contribute to impaired cell division.
Similarly, we detected increased U12-dependent intron
retention inMYO10 and SRSF10, and also in TMEM41B,
but not in RASGRP3,MYH9, ZDHHC13 or CDK5. With
the exception of MYH9, this is likely due to low levels of
expression that preclude a reliable detection of intron reten-
tion. That we could not detect missplicing ofMYH9 could
be due toNMDdegradation of the aberrant transcripts, but
it could also indicate thatMYH9 missplicing might not be
as pronounced in HeLa cells or even in humans. Further
validation is required to establish whether this is true.
Restoration of SMN by ASO therapy reverses the expression
profile of SMA mice and mitigates intron retention
One important question is whether the restoration of SMN
levels by correcting the splicing of SMN2 exon 7 with an
antisense oligonucleotide (ASO) can reverse the splicing de-
ficiency in the SMA mice along with the other transcrip-
tional characteristics. The effects of small-molecule restora-
tion of SMN were recently examined in a few specific cases
of aberrant splicing (47), but effects on the global scale
and with ASO technology have not yet been characterized.
To address this we treated SMA mice with either saline or
100 g ASO10–29 per gram of body weight using subcuta-
neous injections in two separate doses on PND0 and PND1,
and took out tissue samples for RNA-seq from spinal cord,
brain and liver. This ASO has previously been shown to res-
cue splicing of SMN2 exon 7 (89).
First, we confirmed that ASO treatment restored levels
of SMN2 exon 7 inclusion in all tissues (Figure 7A, Supple-
mentary Figure S16A) to similar levels as previous studies
using SC injections of the ISS-N1 blocking ASO10-27 (44).
Then, we analyzed the gene expression and compared ASO
treated SMAmice with saline treated SMAmice to identify
genes that responded to the treatment. In spinal cord there
was a high degree of overlap between genes that respond to
ASO treatment and genes, which are deregulated in SMA
mice. Between those two groups, there was an inverse cor-
relation indicating reversal of the gene expression profile
consistent with a reversal of the phenotype (Figure 7B) and
with earlier microarray findings (46). The same was true in
brain and liver, although the effects were less pronounced
(Supplementary Figure S16B and C). Similarly, when we
analyzed splicing changes with the Cufflinks annotation, we
found that there was an inverse correlation between splicing
changes in SMA mice and those in ASO treated mice, indi-
cating a reversal of the alternative splicing (Supplementary
Figure S17).
We then compared the pathways previously observed to
be significantly altered in SMA mice, and found that the
majority were reversed in the ASO treated SMA mice (Fig-
ure 7C and D). Importantly, cellular stress seemed to be al-
leviated as the expression levels of the stress markers Mt1
and Mt2 were down-regulated to heterozygous levels in
the ASO treated SMA mice (Figure 7E). Furthermore, the
axon guidance pathway activity was increased in the ASO
treated SMA mice relative to saline treated SMA mice. Al-
though we observed a trend indicating up-regulation, the
increase in Cxcl12 and Cxcr4 levels did not reach signifi-
cance in the qPCR validation (Figure 7E, Supplementary
data S1). This could indicate that the phenotype is not com-
pletely reversed, or that the axon guidance pathway may
also be down-regulated through factors other than Cxcl12
and Cxcr4.
Next, we analyzed the effect of ASO treatment on U12-
dependent intron retention and found that increasing SMN
levels through ASO treatment reverses the aberrant intron
retention in SMA mice and promotes correct splicing of
U12-dependent introns (Figure 8A). While we did not ob-
serve correction of splicing in the brain, this may be due to
lower ASO efficacy in the brain as indicated by the observed
levels of SMN2 exon 7 splicing correction (Figure 7A).
The degree of overlap between introns that were cor-
rected in spinal cord versus liver was relatively small (Fig-
ure 8B), especially considering that more than half of the
aberrantly retained U12-dependent introns in spinal cord
were also aberrantly retained in the liver (Figure 4C). Sim-
ilarly, there was little overlap of introns corrected in spinal
cord ofASO treated SMAmice and those aberrantly spliced
relative to heterozygous controls (Figure 8C). In the liver
however, almost three out of four corrected introns had pre-
viously been detected as aberrantly retained, including the
U12-dependent intron in Rasgrp3. This indicates an overall
improvement in the splicing of U12-dependent introns in
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Figure 7. ASO treatment reverses the expression and splicing profiles of SMA. (A) ASO treatment increases inclusion ofSMN2 exon 7. Inclusion percentage
were estimated from RT-PCR product sizes quantitated on a fragment analyzer. (B) Scatter plot of log2 fold-changes of significant genes in spinal cord of
ASO treated mice relative to saline treated SMA mice and log2 fold-changes of the same genes in SMA mice relative to heterozygous controls. Genes that
are significant in both comparisons are indicated in red and Pearson’s correlation is indicated for these genes. (C) Heatmap of the average gene expression
of genes in pathways significantly altered in the spinal cord of SMA mice relative to healthy controls. Gene expression values are derived from regularized
log values and the normalized across samples setting the average to zero. (D) Barplot showing unadjusted P-values for the testing of reversal of the pathway
in ASO treated mice relative to untreated SMAmice. (E) qPCRmeasurements of genes previously found to be deregulated in the spinal cord of SMAmice.
the liver, which is consistent with the observed higher cor-
rection of SMN2 exon 7 inclusion.
Using qPCR we specifically confirmed that ASO treat-
ment restores splicing of the U12-dependent intron in
Baz1b to levels equivalent to those in heterozygous control
mice (Figure 8D). Likewise, Myo10 splicing is restored in
the spinal cord of ASO treated SMA mice and the reten-
tion is ameliorated in liver as well (Figure 8D).
Interestingly, among the genes with rescued U12-
dependent intron retention in spinal cord there were sev-
eral encoding the pore-forming subunit in voltage-gated
Ca2+ channels: Cacna1a, Cacna1b, Cacna1c, Cacna1e and
Cacna1h. Disruption of Ca2+ channel clustering and cel-
lular Ca2+ homeostasis is one of the hallmarks of SMA
(90,91), and elevated Ca2+ level leads to activation of Cdk5
through cleavage of p35 (92).We therefore suggest that aber-
rant splicing of U12-dependent introns in genes encoding
Ca2+ channels contribute to disrupted Ca2+ homeostasis
leading to axon terminal dysfunction and Cdk5 hyperactiv-
ity.
DISCUSSION
SMA has been known for long to be caused by decreased
levels of SMNprotein, but themolecular pathways involved
in the manifestation of the clinical symptoms are not clearly
understood. Among important questions raised, is the ex-
tent of the involvement of diverse functions of the SMN
protein in the disease pathology, in particular the question
of the role of aberrant splicing has been raised, but without
a clear answer emerging.
Here, we used RNA-seq to investigate the consequences
of low levels of SMN on the transcriptome in multiple tis-
sues in SMA mice, and found evidence to support aberrant
splicing as one of the contributing disease mechanisms in
SMA.
In particular, we found that stress was elevated in several
tissues and that in the spinal cord the axon guidance path-
way was down-regulated. Cell division pathways were also
significantly down-regulated across all tissues. Treatment of
SMA mice with an ASO that restores splicing of SMN2
exon 7 resulted in decreased stress and reactivation of the
axon guidance pathway as well as cell division pathways,
consistent with the remarkable reversal of the phenotype
previously observed (44). Interestingly, up-regulation of the
stress-genesMt1 andMt2was also reported in an earliermi-
croarray study of gene expression in the spinal cord in the
7 SMA model at PND13 (29), indicating that the stress
is characteristic of SMA. Similarly, angiogenesis seemed to
be inhibited across all tissues examined in SMAmice, possi-
bly limiting the supply of nutrients, growth factors and oxy-
gen to developing cells. Consistent with a hypoxic stress re-
sponse, hypoxia-inducible factor Hif-3α was up-regulated
app. 2.5–4-fold in all tissues at PND5 in SMA mice, which
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Figure 8. ASO treatment restores correct splicing of U12-dependent introns in SMA mice. (A) Volcano plots of U12-dependent introns in brain, spinal
cord and liver of ASO treated SMA mice. Significantly differentially retained introns are indicated in red. Non-significant introns with fold-changes >2
are indicated in blue. Values exceeding chart limits are plotted at the corresponding edge and indicated by upward facing triangle. (B) Overlap of introns
with significantly improved splicing in liver and spinal cord of ASO treated SMAmice. SMA = saline treated SMAmice, ASO = ASO treated SMAmice.
(C) Overlap of introns significantly retained in SMAmice and introns significantly improved in ASO treated SMAmice in spinal cord and liver. (D) qPCR
analysis of BAZ1B/Baz1b andMYO10/Myo10U12-dependent intron splicing in HeLa SMN-KD samples, and spinal cord and liver in ASO treated SMA
mice.
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was also observed to be up-regulated in a previous microar-
ray study of spinal cord (29). However, unlike Zhang et al.
(28) we did not observe alternative splicing of Hif-3α. El-
evated ER stress specific to SMA motor neurons has been
reported (93), but in our data from total spinal cord we did
not find evidence for up-regulation of this pathway, likely
because this stress may be highly specific to the motor neu-
rons.
It could be speculated that many of the transcriptomic
changes identified in this study are activated by cellular
stress, especially by the hypoxic stress response activated in
SMA mice. However, upon examining RNA-seq data from
a study on hypoxic stress (94), we found no indication of in-
creasedU12-dependent intron retention as a response to hy-
poxia or siRNA targeting HIF-1 or HIF-2 (Supplemen-
tary Figure S18). Additionally, up-regulation of p38MAPK
levels following stress has been reported to modulate U12-
dependent introns and increase their splicing (95), but we
only detected changes in the expression of p38MAPK ki-
nases in the liver and muscle at PND5. In the liverMapk11
and Mapk12 were down-regulated, whereas Mapk13 was
up-regulated, and in the muscle Mapk11 was also down-
regulated. Similarly, an earlier study reported that the phos-
phorylation state of p38MAPK isoforms is not altered in
SMA mice (96). Thus, while we cannot rule out that stress
is involved in the observed increase in U12-dependent in-
tron retention, we cannot find evidence to suggest that it is
the primary cause of aberrant U12-dependent intron pro-
cessing. Considering the established role of SMN in snRNP
assembly, it seemsmore likely that decreased SMN levels di-
rectly influence the aberrant processing of U12-dependent
introns. The stress-related changes may be a secondary ef-
fect of the SMA pathology, but as SMN deficiency has been
shown to sensitize cells to stress (97), stress may further ex-
acerbate the symptoms. Treatments that minimize cellular
stress may thus be beneficial to SMA patients.
In addition to elevated cellular stress, cell proliferation
pathways were also down-regulated across the tissues ex-
amined in this study. Specifically, we noted missplicing of
the U12-dependent introns in Baz1b in most tissues, and
in Rasgrp3 in all tissues, and down-regulation of correctly
spliced Rasgrp3 in tissues at both PND1 and PND5. Ras-
grp3 is an activator of Ras, and suppression of Rasgrp3 in-
hibits cell proliferation, whereas over-expression enhances
cell proliferation (77). Similar to others (29,46,98), we also
observed up-regulation of the Cdk1 inhibitor Cdk1na in-
volved in p53-mediated cell-cycle arrest and of several his-
tone cluster 1 genes (Supplementary data S1). Additionally,
U7 snRNP levels are decreased when SMN levels are low
(16), and this may also contribute directly to a decrease in
cell proliferation. SMN may thus directly and through sev-
eral distinct pathways influence cell proliferation in addition
to any stress related inhibition of cell growth.
Comparative analysis of our results from the analysis of
spinal cord at PND5 with two previous microarray stud-
ies that analyzed spinal cord expression in SMA mice vs.
normal and heterozygous controls (28,29) shows similar ex-
pression profiles, but at different time-points (Supplemen-
tary Figure S19). Apart from differences in sensitivities be-
tween RNA-seq and microarrays, one explanation for the
temporal difference could be that the former studies exam-
ined gene expression in the 7 mouse model (99), while we
used the ‘Taiwanese’ model (68). This model has a shorter
life span and appears to have an expression profile at PND5
that ismore similar to the expression profile of the7model
at PND11–13, than at PND7. One possible explanation is
that the general intracellular stress and therefore expression
profile of motor neuron dysfunction persists throughout a
longer period, and consistent with a shorter lifespan, the
cellular stress is more severe at an earlier time-point in the
‘Taiwanese’ model, than in the 7 model.
Similar to previous studies (28,29,76) we also observed
alternative splicing of Uspl1 across all tissues and we also
noticed alternative splicing of genes associated with U
snRNPs, such as Snrpa1 and Rnpc3, that were likewise ob-
served in previous exon-array studies (28,29). Although the
change in splicing of Uspl1 in the spinal cord was appar-
ent from the RNA-seq data it was not statistically signif-
icant, but we were able to confirm it in a PCR reaction
(data not shown). Uspl1 was recently reported to interact
with snRNA loci, and knock-down of Uspl1 resulted in de-
creased snRNP levels (100). The exon which is up-regulated
in Uspl1 would seemingly lead to more production of the
Uspl1 protein, and in liver and muscle, we observed up-
regulation of Uspl1 transcripts. Similarly, it is noteworthy
that we observed significant up-regulation of Snrpa1 in all
tissues at both PND1 and PND5, while we observed de-
creased intron retention in Snrpa1, which could lead to the
increased expression, as fewer transcripts would be NMD-
sensitive. These changes do not appear to be alternative
splicing caused by defective splicing, but insteadmay be reg-
ulated splicing of genes as a response to the low SMN lev-
els. These alternative splicing events may also be a specific
response to altered snRNP levels and using primers from
(28), we examined snRNA levels in treated and untreated
SMA mice at PND5, as well as HeLa cells with SMN-KD.
In the liver, we observed down-regulation of several snR-
NAs in SMAmice, which was corrected by ASO treatment,
and we also observed trends towards decreased snRNA lev-
els in the HeLa cells (Supplementary Figure S20). Surpris-
ingly, we did not observe the same in spinal cord and brain,
in contrast with earlier studies (26,28,30). These conflict-
ing results in relation to earlier studies may be due to dif-
ferences in the analysis methods employed, such as specific
immuno-precipitation of mature snRNP complexes vs total
RNA, and cDNA synthesis using specific snRNA primers
versus randomprimers. Tissue differences between liver and
CNS may be due to a number of reasons such as differ-
ences in snRNA turnover, differences in RNA sample sta-
bility, and the proportion of cells affectedwithin the sample,
whichmay be higher in the liver. Therefore, although we did
not detect differences in snRNA levels in all tissues, there
may still be a significant perturbation in the levels of active
snRNP complexes in the affected tissues, as indicated by the
altered expression and splicing of several snRNP associated
proteins.
It is possible that the alternative splicing of splicing-
regulatory proteins, such as SR proteins, is also a case of
regulated alternative splicing in response to the disruption
of the splicing machinery, rather than being directly caused
by decreased splicing fidelity. However, if SR proteins are
more sensitive to decreased splicing fidelity, increasing mis-
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splicing of SR proteins may explain in part the increasing
levels of aberrant splicing with the SMA stage in animal
models, as suggested previously (76). In general, there is lit-
tle overlap between the detected splice changes in this study
and a recent exon array study (Supplementary Figure S21),
which may be explained by the differences in assay tech-
nology and animal model. Thus, we did not detect alterna-
tive splicing ofChodl orUba1, which have been investigated
previously (29,101,102), while we detected minor skipping
in the Nrxn2 gene of an exon different from the previously
reported (103). We did however detect down-regulation of
the Uba1 gene in spinal cord, and also aberrant retention
of U12-dependent introns in the Uba3, Ubeh2, and Ubl5
genes that support disruption of the ubiquitin homeostasis
as previously suggested (101). We also detected missplicing
of U12-dependent introns in UBA3 and UBEH2 in HeLa
SMN-KD experiments, indicating that disruption of this
pathway through U12-dependent intron retention may be
present in human patients as well.
In a recent RNA-seq study ofmicro-dissectedmotor neu-
rons, Zhang et al. (104) reported up-regulation of the C1q
genes in SMA motor neurons, and consistent with this, we
observed up-regulation of the C1qa, C1qb and C1qc genes
in the spinal cord at PND5 (Supporting data S1). This in-
dicates that it is possible to detect changes at PND5 that
may be causative at PND1, but that changes are more pro-
nounced at PND5 and therefore more easily detected. This
underscores the relevance of studying mice at later stages
in the disease progression. Zhang and coworkers also re-
ported prominent skipping of the Z exons in agrin, but we
did not find any evidence of missplicing in the Agrn gene in
the spinal cord or brain samples taken at PND1 or PND5.
It is possible that this skipping is activated in a limited cell
population and therefore not apparent in our total spinal
cord samples.
One major issue raised by this and other studies, is the
lack of transcriptomic changes at PND1 prior to symp-
toms, which makes it difficult to differentiate between pri-
mary changes directly caused by SMN loss and secondary
changes caused by a general cell dysfunction, when exam-
ining the transcriptome at a later symptomatic point, such
as PND5. One explanation could be that a reduced SMN
level is not critical during embryonic development and that
it does not manifest significantly until a time-point later
than PND1. Decreased SMN protein levels are caused by
skipping of exon 7 and it is possible that during the em-
bryonic stage SMN2 exon 7 is included at sufficient lev-
els due to altered expression of splicing factors. During the
postnatal period the SMN protein levels are then slowly de-
creased after which cellular dysfunction becomes apparent.
Importantly, both we and others detect missplicing of splic-
ing factors in SMA mice (76), including Tial1, which acti-
vates SMN2 exon 7 (105). Furthermore, it has been demon-
strated that there is a feedback loop where exon 7 skipping
leads to progressively increased skipping of SMN2 exon 7
(106,107). Even a modestly higher SMN2 exon 7 inclusion
level during embryonic development may thus result in a
substantially improved SMN protein amount, which may
be sufficient to ensure normal embryonic development, but
postnatally SMN levels drop significantly due to the nega-
tive feedback loop of increased exon 7 skipping.
Despite this, we do observe changes in the expression
of some genes at PND1 that are correlated with changes
observed at PND5, and also missplicing of some U12-
dependent introns. It is likely that the SMNdecrease ismore
severe in some cells than in others, and this can explain the
lower levels of missplicing when examining the total tissue.
It also indicates that U12-dependent intron retention is part
of the early response to decreased SMN levels, which is con-
firmed by the analysis on SMN knockdown in HeLa cells.
However, because of NMD clearing of aberrantly spliced
transcripts this may be very difficult to detect, and there-
fore underreported.
In this study, we identified U12-dependent intron reten-
tion in all examined tissues (Table 5), indicating that all
cells experience some level of dysfunction during SMN de-
ficiency, and this was confirmed in the non-neuronal HeLa
cell line. Many of the genes were affected in multiple tissues
while others were completely unaffected, indicating that
some genes have an increased sensitivity to aberrant U12-
dependent intron splicing. In order to characterize what
might sensitize some U12-dependent introns to decreased
SMN levels, we examined their properties. We found that
low GC-content of the introns was associated with intron
retention (Supplementary Figure S22). In most tissues, the
introns had a statistically significant lowerGC-content than
introns that were not affected. Interestingly, in the case of
the U12-dependent introns responding to ASO treatment
in the spinal cord, there was an inverse relationship be-
tween the amount of correction and the GC-content (Sup-
plementary Figure S22). While we cannot rule out that se-
quencing itself biases this analysis, as sequences with lower
GC-content are more likely to be amplified during library
construction, we did not observe the same pattern for the
U2-dependent introns where the significantly retained U2-
introns were more likely to have higher GC-content (data
not shown). GC-content may thus be one of the factors that
differentiate sensitive U12-dependent introns from robustly
spliced U12-dependent introns.
Several lines of evidence support the involvement of
aberrant U12-dependent intron splicing in SMA pathol-
ogy rather than missplicing by the major spliceosome.
Firstly, several studies have reported on specific decreases
in the minor snRNPs rather than in the major snRNPs
(27,30,31). Secondly, SMN depletion results in motor neu-
ron defects in a number of species that are evolutionary dis-
tinct and vary greatly in size, from fruit flies to humans.
The defect therefore seems to be highly conserved and U12-
dependent introns do indeed tend to be evolutionary con-
served (108). Missplicing of a few key exons or retention
of U2-dependent introns spliced by the major spliceosome
would be unlikely to be conserved across species so evolu-
tionary distinct as fruit flies and humans. This indicates that
while missplicing by the major spliceosome might also con-
tribute to specific pathologies in various animal models and
in humans, the common pathology of SMA is more likely
to be affected by impaired minor spliceosome activity.
The question therefore remains how increased U12-
dependent intron retention is particularly detrimental to the
function of motor neurons. Earlier studies have indicated
that retention of the U12-dependent intron in Tmem41b in
proprioceptive neurons is higher than inmotor neurons and
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Table 5. Genes with U12-dependent intron retention validated with qPCR at PND5
Gene Brain
Spinal
cord Liver Muscle Gene description Related biological processes and functions
Baz1b R,Q R,Q R,Q R* Bromodomain Adjacent To Zinc Finger
Domain, 1B
Chromatin remodelling, DNA damage response
Cdk5 R R R,Q R Cyclin-dependent kinase 5 Synaptic plasticity, neuronal migration
Myh9 R,Q R,Q R,Q R,Q Myosin, heavy chain 9 Cytokinesis, cell shape, cytoskeleton
reorganization, beta-actin associated
Myo10 Q Q R,Q R,Q Myosin X Axon guidance and growth, neuronal migration,
actin binding, vesicle transport
Rasgrp3 R,Q R,Q R,Q R,Q RAS Guanyl Releasing Protein 3 Cell growth, cell migration
Srsf10 R,Q R,Q R,Q R,Q Serine/Arginine-Rich Splicing Factor 10 Regulation of mRNA splicing, neuronal
development
Zdhhc13 R,Q R R,Q R,Q Huntingtin-Interacting Protein 14-Related
Protein
Neuronal, bone development
R = significant in RNA-seq, Q = significant in qPCR. * = not tested with qPCR in the tissue.
that it is the disruption of the interplay between neuronal
populations that motor neurons are particular sensitive to
(32). Furthermore, motor neuron cell-nonautonomous res-
cue of SMAmice (45) strongly indicates that motor neuron
function is disrupted by peripheral dysfunction as well as
motor neuron specific dysfunction. Even so, our data here
points to several U12-dependent introns beingmisspliced in
spinal cord tissue that may directly influence neuronal func-
tion.Myo10 showed increasedU12-dependent intron reten-
tion and decreases of correctly splicedMyo10 in brain and
spinal cord, while there was less aberrant splicing in the liver
and muscle. Myo10 regulates axonal growth and neuronal
migration (78,79,109) and has additionally been reported to
regulate vesicle transport along tunneling nanotubes (TNT)
in neuronal cells (110). As the changes in splicing ofMyo10
seem to be more pronounced in the CNS than in periph-
eral tissue, missplicing of Myo10 may represent a crucial
neuron-specific event that can explain some of the neuron-
specific characteristics of SMA.Additionally, missplicing of
U12-dependent introns in the voltage gated Ca2+ channel
subunit genes could lead to the disruption of Ca2+ chan-
nel clusters at axon terminals and cellular Ca2+ homeosta-
sis previously reported as hallmarks of SMA (90,91). These
U12-dependent introns are additionally conserved and are
be found in Ca2+ channel genes in SMA animal models.
Since changes in Ca2+ levels can lead to hyperactivation
of Cdk5 (92), we propose that aberrant splicing of U12-
dependent introns in genes encoding subunits in the Ca2+
channels contribute to disrupted Ca2+ homeostasis lead-
ing to axon terminal dysfunction and Cdk5 hyperactivity,
which in turn may lead to motor neuron death. Interest-
ingly, the increased oxidative stress as indicated by elevated
Hif-3α, Mt1, and Mt2 expression may also influence Ca2+
levels, which might contribute further to the downstream
effects of disrupted Ca2+ homeostasis. These genes may
be particularly sensitive to aberrant U12-dependent intron
splicing as they contain two distinct U12-dependent introns
that each may be affected. Crucially, very recently aber-
rant processing of U12-dependent introns was reported in
Amyotrophic Lateral Sclerosis (ALS) associated FUS mu-
tants (111), and among the affected genes were CACNA1B,
CACNA1C, CACNA1E andMYO10. Both SMA and ALS
are characterized by loss of motor neuron function and dis-
ruptedCa2+ homeostasis and these genesmay therefore rep-
resent interesting candidates as therapeutic targets in both
SMA and ALS.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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